When coupled to mass spectrometry (MS), energetics-based protein separation (EBPS) 2 techniques, such as thermal shift assay, have shown great potential to identify the targets of a 3 drug on a proteome scale. Nevertheless, the computational analyses assessing the confidence of 4 drug target predictions made by these methods have remained rudimentary and significantly 5 differ depending on the protocol used to produce the data. To identify drug targets in datasets 6 produced using different EBPS-MS techniques, we have developed a novel flexible 7 computational approach named TargetSeeker-MS. We showed that TargetSeeker-MS 8 reproducibly identifies known and novel drug targets in C. elegans and HEK293 samples that 9 were treated with the fungicide benomyl and processed using two different EBPS techniques. We 10 also validated a novel benomyl target in vitro. TargetSeeker-MS, which is available online, 11 allows for the confident identification of targets of a drug on a proteome scale, thereby 12 facilitating the evaluation of its clinical viability. 13 14 Keywords: 15 Bioinformatics / Drug target discovery / Mass spectrometry / Proteomics / Thermal shift assay.
that have been reported to be affected by benomyl, such as "Aldehyde catabolic process" and 20 "Cellular aldehyde metabolic process" (Figure 3D ; Supplementary Table S6 for complete 21 enrichment analysis results) 16,18 . 3 assess the significance of benomyl binding. A green row represents a protein that was also predicted as a benomyl target in the TSA/C. elegans.
1
In order to test the ability of the TargetSeeker-MS algorithm to accurately identify drug targets in 2 samples that were separated using a different EBPS-MS method, we applied our algorithm to the 3 TSA-C. elegans dataset (Dataset 2). Combining two replicate TSA analyses of benomyl-treated 4 samples into a single TargetSeeker-MS analysis allowed the algorithm to identify 278 benomyl 5 targets with a FDR < 0.01 and 331 benomyl targets with a FDR < 0.05 (Supplementary Table   6 S7).
7
Even though Dataset 2 was processed using a similar approach to that described in 8 Savitski et al. (i.e. using the same mechanism: heat destabilization), TargetSeeker-MS again 9 identified more drug targets at high-confidence FDRs than the Z-score approach or the Savitski 10 et al. method ( Figure 4A ). Interestingly, 285 proteins in Dataset 2 that were assigned a FDR < 11 0.05, were associated with a relatively low FSD (< 0.2) ( Figure 4B ). This result is likely Figure S8 ). This decreased variation in fractionation profiles therefore allows TargetSeeker-MS 15 to assign high-confidence FDRs to even small changes in protein fractionation profiles upon 16 drug treatment. To maximize sensitivity we therefore opted to not apply a FSD threshold for all 17 data produced using TSA-MS. Nevertheless, in order to maintain a high level of confidence in 18 TargetSeeker-MS predictions, we only retained as putative drug targets proteins that were 19 assigned by the algorithm a FDR < 0.05 in both replicate TSA analyses of benomyl-treated 20 samples when analyzed independently (Supplementary Table S8 , S9, and S10). This process 21 yielded a list of 154 benomyl-binding proteins in the TSA/C. elegans dataset. These proteins are are biological processes that have been reported to be linked to benomyl 19,20 ( Figure 5C and 1 Supplementary Table S16 ). GAPDH is among the H. sapiens proteins for which a C. elegans ortholog was not a predicted as 2 a benomyl target. To our knowledge, GAPDH activity was never previously reported to be 3 affected by benomyl nor was the protein shown to be bound by the compound. We therefore 4 validated the TargetSeeker-MS' prediction from the Dataset 3 using an orthogonal in vitro 5 approach (see Methods). Figure 5D shows that the enzymatic activity of GAPDH is reduced with 6 an increasing concentration of benomyl, with activity reduced approximately by 50% at 25 uM.
This effect confirms the TargetSeeker-MS prediction that GAPDH is bound by benomyl and that 8 this binding affects the in vitro functionality of GAPDH. TargetSeeker-MS is compatible with most MS quantification techniques. 12 In this study, spectral counting was used to build protein fractionation profiles to illustrate that in protein fractionation profiles that are consistent across all replicates. This may particularly be 20 the case for low abundance proteins for which slight changes may be easier to detect with an 21 increase quantification resolution provided by intensity-based quantification techniques.
TargetSeeker-MS' applications for therapeutic discovery
1 EBPS-MS approaches coupled to TargetSeeker-MS can play an important role in the drug 2 discovery process. For instance, high-throughput screenings can allow the identification of a 3 small set of compounds modulating a certain target pathway. These compounds can then be 4 tested against a complex proteome such as the one of a human cell to identify drug bindings and 5 any potential deleterious protein interactions. In the future, EBPS-MS approaches could be 6 applied using TargetSeeker-MS to identify the targets of drugs in induced pluripotent stem cells 7 (iPSCs) and potentially allow the design of better therapeutics. The rapidly growing field of drug repositioning depends on the use of techniques like EBPS-MS 6 for the systematic identification of the targets of a drug. The TargetSeeker-MS software package 7 will facilitate the implementation of these techniques and will have a significant impact on the 8 field. Over time the drug discovery pipeline has become increasingly long and costly. Indeed, it 9 takes on average 13.5 years for a drug to reach the market from the start of the investigation 29 .
10
The drug discovery process is also highly failure-prone with a success rate of less than 10% 29 .
11
Drug repositioning is an effort to test whether compounds for which the safety is known and that 12 were approved by organizations such as the FDA could have applications for treatment of 13 disease processes other than the one they were originally designed for. This accelerates the drug 14 discovery process and minimizes the expense and failure risks. Success stories such as 15 duloxetine, which was originally developed to treat depression and is now also used to improve 16 the condition of stress urinary incontinence victims 30 , and crizotinib, which was created to treat 17 anaplastic large-cell lymphoma and was repurposed for the treatment of non-small-cell lung 18 cancer 31 , will hopefully become more common with the increased popularity of EBPS-MS and the use of TargetSeeker-MS. 1 targets in complex proteome, no user-friendly approaches have been proposed to assess the 2 confidence of drug binding predictions. We have shown that TargetSeeker-MS can identify high-3 confidence drug targets with a limited number of control samples. We also demonstrate that 4 TargetSeeker-MS recapitulates predictions of benomyl targets using different EBPS-MS 5 techniques and processing samples from different organisms. In conclusion, our algorithm will 6 favor the growth of the applications of EBPS-MS techniques and improve their impact the field 7 of drug discovery.
8

METHODS
9
Method overview 10 We propose a computational approach, TargetSeeker-MS, for the identification of drug targets in 11 energetics-based protein separation (EBPS) coupled to mass spectrometry (MS) datasets. The
12
Bayesian inference approach assesses the confidence that a protein is bound by a given 13 compound. We first describe the two EBPS procedures used in this manuscript (DiffPOP and 14 Thermal shift assay) and the mass spectrometry analysis. We then present TargetSeeker-MS 15 machine learning algorithm. Figure 1 graphically depicts our approach. Human embryonic kidney cell lysate (HEK293) was prepared from HEK293 cells grown in supplemented with penicillin and streptomycin. Cells were grown (37 o C/5% CO 2 ) to 1 approximately 80% confluence in tissue culture flasks. Cells were washed twice with DPBS, 2 scrapped from flasks, supplemented with protease inhibitor cocktail (Roche) and lysed by 3 sonication. Protein concentration was determined by BCA assay, lysate was kept at -80 o C until 4 use.
5
C. elegans and HEK293 lysate samples were aliquoted and volume adjusted so that they 6 contained five hundred micrograms of proteins in a final volume of 250 µL containing 40 % 7 Phosphoprotein Buffer A (ClonTech). Nineteen aliquots of C. elegans lysate were utilized, seven 8 of them were treated with benomyl, while twelve were left untreated (controls). In addition, six 9 aliquots of HEK293 human embryonic kidney cell lysate were utilized, four were left untreated 10 (controls), while two were treated with benomyl (see below).
12
Benomyl treatment and DiffPOP protein separation 13 Lysates of HEK293 and C. elegans were incubated with benomyl prior to fractionation. Benomyl 14 (5ul of 10mM stock dissolved in DMSO) was added for the drug treated samples, 5ul of DMSO 15 was added to the control samples. The DiffPOP method was carried out with sequential additions 16 of denaturing solution of 90 % methanol/1% acetic acid (3.75, 8.25, 12.5, 16.25, 20, 42.5, 65, 17 212.5 and 2000 µL). Each addition was followed by vigorous vortexing and centrifugation 18 (18000 x g for 10 min at 4ºC). The supernatant was transferred to a new Eppendorf tube, 19 denaturing solution was added, sample was vortexed and centrifuged. The process was repeated 20 to produce ten pelleted fractions. All resulting pellets were washed with 400 µL ice-cold acetone 21 and centrifuged (18000 x g for 10 min at 4ºC). Pellets were air-dried and digested with trypsin fractions the sample is divided into and " ? / , where = 1, …, , is the spectral count of in 1 fraction . " # is defined similarly for untreated samples . Fractionation profiles " # and " / are 2 computed for all ∈ , where is the set of all proteins that were identified with more than 5 3 spectral counts across all fractions of a sample. Finally, let the fractionation profiles be 4 normalized such that final protein fractionation profiles are defined as follows: "
. " # is obtained similarly. We hypothesize that upon the binding of a drug to a protein, the stability of this protein 8 will be changed. This will affect the fractionation profile of that protein. To measure the change 9 in the fractionation profiles of a protein in the treated and untreated samples we compute the 10 distance between the fractionation profiles of a protein between the drug treated sample " / and 11 the untreated samples " # as the Euclidean distance . We then , to ensure that the measure falls between 0 and 1 inclusively. We 13 then define the similarity " #,/ for between two samples' fractionation profiles " # and " / as 1-14 ′ " # , " / .
16
Significance assessment of fractionation profile changes 17 Biological and technical variation may cause fractionation profiles to differ. Such a variation can 18 be captured by computing the similarity " # % ,# ' of two fractionation profiles " # % and " # ' of a 19 protein obtained from two untreated samples ) and * under the same experimental conditions.
20
A model specifying for each protein the null distribution of the similarity between untreated 21 protein fractionation profiles could therefore be built. Nevertheless, a large number of untreated samples would be required to estimate this distribution accurately. Processing such large 1 numbers of samples with an EBPS-MS would be lengthy and consume vast amounts of 2 resources. However, we showed that using a small number of untreated samples (e.g. four) and 3 assuming that the proteins with similar similarity average values between the different samples 4 will share a similar null distribution, we can build a noise model of the fractionation profiles by 5 pooling proteins within a given similarity range. Such a model can then allow us to evaluate the 6 significance of the difference of the similarity between a treated sample and the untreated ones.
7
We used an approach inspired by a previously described method used to assess the confidence of 8 protein-protein interactions 36 to build this model and to assess the significance of the similarity 9 difference between treated and untreated samples. Our novel computational approach is 10 described below.
12
Step 1 , the average of the similarity between all fractionation profiles except those of the sample pair 1 ( ) , * ). We therefore assume that " U# % ,# ' represents a fair approximation of " # . Now let be a 2 100×100 matrix and , represent the frequency where " # % ,# ' • 100 = and provides us a good estimate of the noise of the similarity between two fractionation profiles.
Step 2: Posterior distribution of the mean similarity between fractionation profiles from 1 untreated samples 2 Using Bayes' rule and assuming the conditional independence of the similarity observations 3 given their true means, the posterior distribution of " # is computed as follows: Step 3: Significance assessment 11 The goal of TargetSeeker-MS is to assess the significance of the change in the fractionation 12 profile of each protein in untreated samples and a drug treated sample. In order to do so, we first 13 compute the average of the similarity values between " / and " # ∀ ∈ as follows, " #,/ = 14 ‡ N O,P O∈W |W|
. We then assess the significance of the change in similarity for the drug treated Step 4: False discovery rate estimation Step 5: Biological replicates of drug treated samples 4
To maximize the stringency of its drug target predictions when given biological replicates of 5 drug treated samples, TargetSeeker-MS allows the user to analyze both replicates independently 6 and to report the proteins that are considered high-confidence drug targets in all replicates. between treated and untreated samples. FDRs were then associated to each -value as follows:
To investigate the mechanism of action of benomyl, we evaluated the statistical enrichment of 2 Gene Ontology terms 37 among the proteins predicted as its targets by TargetSeeker-MS in the 3 three different datasets using Ontologizer 38 . We tested the enrichment of molecular functions, 4 biological processes, and cellular components (with the complete set of proteins associated with 5 a fractionation profile as background Supplementary Table S3 : Benomyl treated sample 2 C. elegans proteins identified through Figure 5D .
